Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in Type 2 diabetes individuals: a cohort study
Tóm tắt
We aimed to assess whether high-density lipoprotein (HDL) cholesterol modifies the association between adiponectin and incident cardiovascular (CV) morbidity and mortality in Type 2 Diabetes Mellitus (T2DM) and vice versa. At baseline, 106 T2DM participants with various degrees of renal function were enrolled and followed up over a period of 7 years with fatal/nonfatal CV events as outcome. During the follow-up, 49 participants experienced incident CV events (28 fatal, 21 nonfatal). On univariate Fine and Gray sub-hazard models, HDL cholesterol was a strong modifier of the association between adiponectin and CV outcomes both on crude (P = 0.011) and gender- and eGFR-adjusted models (P = 0.010). The protective effect for CV events portended by a fixed increase in adiponectin (1 μg/ml) was progressively higher across increasing values of HDL cholesterol. Moreover, plasma adiponectin also modified the protective effect of HDL on CV outcomes both in crude and multivariate analyses. We found a mutual effect modification between adiponectin and HDL as risk factors of CV events in participants with T2DM. Our results are coherent with the hypothesis that HDL cholesterol might play a pivotal role in the interpretation of the association between adiponectin and the risk of adverse CV outcomes in this population.
Tài liệu tham khảo
Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JW (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26(2_suppl):25–32
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Investig 116(7):1784–1792
Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH (2006) Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114(7):623–629
Shibata R, Murohara T, Ouchi N (2012) Protective role of adiponectin in cardiovascular disease. Curr Med Chem 19(32):5459–5466
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20(6):1595–1599
Kishida K, Funahashi T, Shimomura I (2014) Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 28(1):119–130
Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103(8):1057–1063
Shimada K, Miyazaki T, Daida H (2004) Adiponectin and atherosclerotic disease. Clin Chim Acta 344(1–2):1–12
Nofer J-R, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161(1):1–16
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
Roumeliotis S, Roumeliotis A, Panagoutsos S, Giannakopoulou E, Papanas N, Manolopoulos VG, Passadakis P, Tavridou A (2017) Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. J Diabetes Complications 31(10):1527–1532. https://doi.org/10.1016/j.jdiacomp.2017.06.012
Tavridou A, Georgoulidou A, Roumeliotis A, Roumeliotis S, Giannakopoulou E, Papanas N, Passadakis P, Manolopoulos VG, Vargemezis V (2015) Association of plasma adiponectin and oxidized low-density lipoprotein with carotid intima-media thickness in diabetic nephropathy. J Diabetes Res 2015:507265. https://doi.org/10.1155/2015/507265
De Mutsert R, Jager KJ, Zoccali C, Dekker FW (2009) The effect of joint exposures: examining the presence of interaction. Kidney Int 75(7):677–681
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509
Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA (1984) Regression modelling strategies for improved prognostic prediction. Stat Med 3(2):143–152
Tripepi G, Jager KJ, Dekker FW, Zoccali C (2008) Testing for causality and prognosis: etiological and prognostic models. Kidney Int 74(12):1512–1515
Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R (2015) Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol 22(3):276–283
Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, Kim SY, Lee HK, Shimomura I, Park KS (2008) Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 196(1):398–404
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13(1):134–141
Abdallah E, Waked E, Nabil M, El-Bendary O (2012) Adiponectin and cardiovascular outcomes among hemodialysis patients. Kidney Blood Press Res 35(4):247–253
El-Shafey EM, Shalan M (2014) Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients. Ther Apher Dial 18(2):185–192
Kacso I, Potra A, Bondor C, Moldovan D, Rusu C, Patiu I, Racasan S, Orasan R, Vladutiu D, Spanu C (2015) Adiponectin predicts cardiovascular events in diabetes dialysis patients. Clin Biochem 48(13–14):860–865
Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving H-H, Vionnet N, Rossing P (2008) Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 74(5):649–654
Ohashi N, Kato A, Misaki T, Sakakima M, Fujigaki Y, Yamamoto T, Hishida A (2008) Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 47(6):485–491
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Focà A, Paroni R, Malatino LS, Investigators C (2000) Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens 18(9):1207–1213
Markaki A, Psylinakis E, Spyridaki A (2016) Adiponectin and end-stage renal disease. Hormones 15(3):345–354
Gasbarrino K, Gorgui J, Nauche B, Côté R, Daskalopoulou SS (2016) Circulating adiponectin and carotid intima-media thickness: a systematic review and meta-analysis. Metabolism 65(7):968–986
Hayashi M, Shibata R, Takahashi H, Ishii H, Aoyama T, Kasuga H, Yamada S, Ohashi K, Maruyama S, Matsuo S (2011) Association of adiponectin with carotid arteriosclerosis in predialysis chronic kidney disease. Am J Nephrol 34(3):249–255
Van Linthout S, Foryst-Ludwig A, Spillmann F, Peng J, Feng Y, Meloni M, Van Craeyveld E, Kintscher U, Schultheiss HP, De Geest B, Tschope C (2010) Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 210(2):438–444. https://doi.org/10.1016/j.atherosclerosis.2010.01.001
Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27(7):1680–1687
Kalehsar NS, Golmohammadi T (2015) Association between serum adiponectin and HDL-C in type II diabetic patients. Global J Health Sci 7(2):243
Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17(9):2599–2606
Coimbra S, Reis F, Nunes S, Viana S, Valente MJ, Rocha S, Catarino C, Rocha-Pereira P, Bronze-da-Rocha E, Sameiro-Faria M, Oliveira JG, Madureira J, Fernandes JC, Miranda V, Belo L, Santos-Silva A (2019) The protective role of adiponectin for lipoproteins in end-stage renal disease patients: relationship with diabetes and body mass index. Oxid Med Cell Longev 2019:3021785. https://doi.org/10.1155/2019/3021785
Wang M, Wang D, Zhang Y, Wang X, Liu Y, Xia M (2013) Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus. Atherosclerosis 229(1):62–70
Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, Schaffler A (2003) Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 545(2–3):103–104. https://doi.org/10.1016/s0014-5793(03)00568-4
Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR (2017) Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev 2017:3081856. https://doi.org/10.1155/2017/3081856
Goldberg RB, Temprosa M, Mele L, Orchard T, Mather K, Bray G, Horton E, Kitabchi A, Krakoff J, Marcovina S (2016) Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism 65(5):764–775
Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, Balasubramanyam A, Tracy RP, Kriska AP, Ballantyne CM (2012) Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. J Lipid Res 53(12):2726–2733
Chan DC, Barrett PHR, Ooi EM, Ji J, Chan DT, Watts GF (2009) Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein AI kinetics in obese and nonobese men. J Clin Endocrinol Metab 94(3):989–997
Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii K-i, Ishigami M (2007) Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 358(4):1091–1095
Van Linthout S, Foryst-Ludwig A, Spillmann F, Peng J, Feng Y, Meloni M, Van Craeyveld E, Kintscher U, Schultheiss H-P, De Geest B (2010) Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 210(2):438–444
Gorgui J, Gasbarrino K, Georgakis MK, Karalexi MA, Nauche B, Petridou ET, Daskalopoulou SS (2017) Circulating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, and mortality: a systematic review and meta-analyses. Metabolism 69:51–66
Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban M-C, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S, Blaha MJ, Martin SS (2016) Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 253:194–208
Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 51(6):1546–1553